SARANAC LAKE — Trudeau Institute has appointed a new president, capping a change in funding streams and direction at the 128-year-old research institute.
Dr. Ronald H. Goldfarb took the helm this week as Trudeau’s sixth president, director and CEO, according to Board of Trustees Chairman Benjamin Brewster.
A scientist, Goldfarb has conducted and managed cancer research for 30 years, having served at the Institute for Cancer Research at the University of North Texas, as deputy director of the University of Pittsburgh Cancer Institute and in managing cancer-drug discovery programs for Pfizer Inc.
Then, in 2002, Goldfarb co-founded Sopherion Therapeutics, a biopharmaceutical company based in Princeton, N.J.
There, his work developed, tested and successfully brought to market the drug Myocet, a medicine used to treat metastatic breast cancer.
In an interview with the Press-Republican, Goldfarb said that project is nearing a transition.
He has generated $140 million in resources for the company in the past decade. The medicine is in use in Europe and Canada. And Sopherion is finishing a final confirmatory trial before the drug reaches the market here.
And with delivery near, he and co-founder Dr. Salvatore Forenza opted to put Sopherion on the market.
“We believe, at this time, it’s appropriate to sell our rights to the drug,” Goldfarb said.
“That would allow the most resources to develop it. We think it has utility to treat a dozen other cancers, and we’ve hired a banker to sell the asset.
“Meanwhile, I was considering other opportunities and was delighted to find the position at Trudeau.”
That the new president has detailed experience bringing research to market as a medical product is no coincidence to the future of Trudeau.
Long-term strategic planning done there in recent years led some administrators to consider options to relocate or build a sister site with access to hospital facilities for clinical trials on human patients.